NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
33
HQH Quote, Financials, Valuation and Earnings
Last price:
$16.32
Seasonality move
:
4.58%
Day range:
$15.90 - $16.40
52-week range:
$15.76 - $19.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
299.7K
Avg. volume:
245.7K
1-year change:
1.56%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HQH
abrdn Healthcare Investors
|
-- | -- | -- | -- | -- |
|
BME
Blackrock Health Sciences Trust
|
-- | -- | -- | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
THQ
Tekla Healthcare Opportunities Fund
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HQH
abrdn Healthcare Investors
|
$16.29 | -- | -- | -- | $0.62 | 0% | -- |
|
BME
Blackrock Health Sciences Trust
|
$37.44 | -- | -- | -- | $0.26 | 0.42% | -- |
|
HQL
abrdn Life Sciences Investors
|
$13.50 | -- | -- | -- | $0.50 | 0% | -- |
|
IBB
iShares Biotechnology ETF
|
$132.73 | -- | -- | -- | $0.06 | 0.29% | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
$21.60 | -- | -- | -- | $0.09 | 1.09% | -- |
|
THQ
Tekla Healthcare Opportunities Fund
|
$18.71 | -- | -- | -- | $0.36 | 10.82% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HQH
abrdn Healthcare Investors
|
-- | 1.083 | -- | -- |
|
BME
Blackrock Health Sciences Trust
|
-- | 0.916 | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | 1.173 | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | 1.446 | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | 1.252 | -- | -- |
|
THQ
Tekla Healthcare Opportunities Fund
|
-- | 0.976 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HQH
abrdn Healthcare Investors
|
-- | -- | -- | -- | -- | -- |
|
BME
Blackrock Health Sciences Trust
|
-- | -- | -- | -- | -- | -- |
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
THQ
Tekla Healthcare Opportunities Fund
|
-- | -- | -- | -- | -- | -- |
abrdn Healthcare Investors vs. Competitors
-
Which has Higher Returns HQH or BME?
Blackrock Health Sciences Trust has a net margin of -- compared to abrdn Healthcare Investors's net margin of --. abrdn Healthcare Investors's return on equity of -- beat Blackrock Health Sciences Trust's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQHabrdn Healthcare Investors-- -- -- BMEBlackrock Health Sciences Trust-- -- -- -
What do Analysts Say About HQH or BME?
abrdn Healthcare Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand Blackrock Health Sciences Trust has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Healthcare Investors has higher upside potential than Blackrock Health Sciences Trust, analysts believe abrdn Healthcare Investors is more attractive than Blackrock Health Sciences Trust.
Company Buy Ratings Hold Ratings Sell Ratings HQHabrdn Healthcare Investors0 0 0 BMEBlackrock Health Sciences Trust0 0 0 -
Is HQH or BME More Risky?
abrdn Healthcare Investors has a beta of 0.769, which suggesting that the stock is 23.068% less volatile than S&P 500. In comparison Blackrock Health Sciences Trust has a beta of 0.680, suggesting its less volatile than the S&P 500 by 32.048%.
-
Which is a Better Dividend Stock HQH or BME?
abrdn Healthcare Investors has a quarterly dividend of $0.62 per share corresponding to a yield of 0%. Blackrock Health Sciences Trust offers a yield of 0.42% to investors and pays a quarterly dividend of $0.26 per share. abrdn Healthcare Investors pays -- of its earnings as a dividend. Blackrock Health Sciences Trust pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQH or BME?
abrdn Healthcare Investors quarterly revenues are --, which are smaller than Blackrock Health Sciences Trust quarterly revenues of --. abrdn Healthcare Investors's net income of -- is lower than Blackrock Health Sciences Trust's net income of --. Notably, abrdn Healthcare Investors's price-to-earnings ratio is -- while Blackrock Health Sciences Trust's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Healthcare Investors is -- versus -- for Blackrock Health Sciences Trust. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQHabrdn Healthcare Investors-- -- -- -- BMEBlackrock Health Sciences Trust-- -- -- --
-
Which has Higher Returns HQH or HQL?
abrdn Life Sciences Investors has a net margin of -- compared to abrdn Healthcare Investors's net margin of --. abrdn Healthcare Investors's return on equity of -- beat abrdn Life Sciences Investors's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQHabrdn Healthcare Investors-- -- -- HQLabrdn Life Sciences Investors-- -- -- -
What do Analysts Say About HQH or HQL?
abrdn Healthcare Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand abrdn Life Sciences Investors has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Healthcare Investors has higher upside potential than abrdn Life Sciences Investors, analysts believe abrdn Healthcare Investors is more attractive than abrdn Life Sciences Investors.
Company Buy Ratings Hold Ratings Sell Ratings HQHabrdn Healthcare Investors0 0 0 HQLabrdn Life Sciences Investors0 0 0 -
Is HQH or HQL More Risky?
abrdn Healthcare Investors has a beta of 0.769, which suggesting that the stock is 23.068% less volatile than S&P 500. In comparison abrdn Life Sciences Investors has a beta of 0.748, suggesting its less volatile than the S&P 500 by 25.182%.
-
Which is a Better Dividend Stock HQH or HQL?
abrdn Healthcare Investors has a quarterly dividend of $0.62 per share corresponding to a yield of 0%. abrdn Life Sciences Investors offers a yield of 0% to investors and pays a quarterly dividend of $0.50 per share. abrdn Healthcare Investors pays -- of its earnings as a dividend. abrdn Life Sciences Investors pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQH or HQL?
abrdn Healthcare Investors quarterly revenues are --, which are smaller than abrdn Life Sciences Investors quarterly revenues of --. abrdn Healthcare Investors's net income of -- is lower than abrdn Life Sciences Investors's net income of --. Notably, abrdn Healthcare Investors's price-to-earnings ratio is -- while abrdn Life Sciences Investors's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Healthcare Investors is -- versus -- for abrdn Life Sciences Investors. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQHabrdn Healthcare Investors-- -- -- -- HQLabrdn Life Sciences Investors-- -- -- --
-
Which has Higher Returns HQH or IBB?
iShares Biotechnology ETF has a net margin of -- compared to abrdn Healthcare Investors's net margin of --. abrdn Healthcare Investors's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQHabrdn Healthcare Investors-- -- -- IBBiShares Biotechnology ETF-- -- -- -
What do Analysts Say About HQH or IBB?
abrdn Healthcare Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Healthcare Investors has higher upside potential than iShares Biotechnology ETF, analysts believe abrdn Healthcare Investors is more attractive than iShares Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HQHabrdn Healthcare Investors0 0 0 IBBiShares Biotechnology ETF0 0 0 -
Is HQH or IBB More Risky?
abrdn Healthcare Investors has a beta of 0.769, which suggesting that the stock is 23.068% less volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.740, suggesting its less volatile than the S&P 500 by 26.046%.
-
Which is a Better Dividend Stock HQH or IBB?
abrdn Healthcare Investors has a quarterly dividend of $0.62 per share corresponding to a yield of 0%. iShares Biotechnology ETF offers a yield of 0.29% to investors and pays a quarterly dividend of $0.06 per share. abrdn Healthcare Investors pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQH or IBB?
abrdn Healthcare Investors quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. abrdn Healthcare Investors's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, abrdn Healthcare Investors's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Healthcare Investors is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQHabrdn Healthcare Investors-- -- -- -- IBBiShares Biotechnology ETF-- -- -- --
-
Which has Higher Returns HQH or IBBQ?
Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to abrdn Healthcare Investors's net margin of --. abrdn Healthcare Investors's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQHabrdn Healthcare Investors-- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- -
What do Analysts Say About HQH or IBBQ?
abrdn Healthcare Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Healthcare Investors has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe abrdn Healthcare Investors is more attractive than Invesco Nasdaq Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HQHabrdn Healthcare Investors0 0 0 IBBQInvesco Nasdaq Biotechnology ETF0 0 0 -
Is HQH or IBBQ More Risky?
abrdn Healthcare Investors has a beta of 0.769, which suggesting that the stock is 23.068% less volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HQH or IBBQ?
abrdn Healthcare Investors has a quarterly dividend of $0.62 per share corresponding to a yield of 0%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.09% to investors and pays a quarterly dividend of $0.09 per share. abrdn Healthcare Investors pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQH or IBBQ?
abrdn Healthcare Investors quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. abrdn Healthcare Investors's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, abrdn Healthcare Investors's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Healthcare Investors is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQHabrdn Healthcare Investors-- -- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- --
-
Which has Higher Returns HQH or THQ?
Tekla Healthcare Opportunities Fund has a net margin of -- compared to abrdn Healthcare Investors's net margin of --. abrdn Healthcare Investors's return on equity of -- beat Tekla Healthcare Opportunities Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQHabrdn Healthcare Investors-- -- -- THQTekla Healthcare Opportunities Fund-- -- -- -
What do Analysts Say About HQH or THQ?
abrdn Healthcare Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand Tekla Healthcare Opportunities Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Healthcare Investors has higher upside potential than Tekla Healthcare Opportunities Fund, analysts believe abrdn Healthcare Investors is more attractive than Tekla Healthcare Opportunities Fund.
Company Buy Ratings Hold Ratings Sell Ratings HQHabrdn Healthcare Investors0 0 0 THQTekla Healthcare Opportunities Fund0 0 0 -
Is HQH or THQ More Risky?
abrdn Healthcare Investors has a beta of 0.769, which suggesting that the stock is 23.068% less volatile than S&P 500. In comparison Tekla Healthcare Opportunities Fund has a beta of 0.935, suggesting its less volatile than the S&P 500 by 6.506%.
-
Which is a Better Dividend Stock HQH or THQ?
abrdn Healthcare Investors has a quarterly dividend of $0.62 per share corresponding to a yield of 0%. Tekla Healthcare Opportunities Fund offers a yield of 10.82% to investors and pays a quarterly dividend of $0.36 per share. abrdn Healthcare Investors pays -- of its earnings as a dividend. Tekla Healthcare Opportunities Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQH or THQ?
abrdn Healthcare Investors quarterly revenues are --, which are smaller than Tekla Healthcare Opportunities Fund quarterly revenues of --. abrdn Healthcare Investors's net income of -- is lower than Tekla Healthcare Opportunities Fund's net income of --. Notably, abrdn Healthcare Investors's price-to-earnings ratio is -- while Tekla Healthcare Opportunities Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Healthcare Investors is -- versus -- for Tekla Healthcare Opportunities Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQHabrdn Healthcare Investors-- -- -- -- THQTekla Healthcare Opportunities Fund-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 4.37% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 8.88% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.98% over the past day.
